| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AS601245 | GDSC1000 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.047 | 0.2 |
| mRNA | KIN001-055 | GDSC1000 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | etoposide | GDSC1000 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | -0.047 | 0.2 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.045 | 0.2 |
| mRNA | pifithrin-mu | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |